Project Grant R43GM146472

Award Date 9/20/23
Completion Date 8/31/24
Dollars Obligated $398K
Federal Grant Program
93.859
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
This $359,490 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will support the development of a suite of deep learning methods for "Single-Cell Genetics". The key products and services to be delivered under this 5-year award, which runs from May 1, 2025 to Feb 28, 2030, include: A novel deep learning model to predict gene expression from DNA sequences, enabling comprehensive...
This Project Grant award of $350,000.00 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop an artificial intelligence-based platform for optimizing peptide-based drug candidates. The key products or services to be delivered include: Methods for encoding non-canonical amino acids and cyclic peptides to enable high-performance machine learning on commercial peptide sequence, activity, stability, and...
This $385,700 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) will fund research at the University of Pittsburgh over a 5-year period from September 2024 to August 2029. The research aims to develop advanced computational and machine learning models that integrate diverse biomedical data, from genetics to transcriptomics and proteomics, to better predict the effects of therapies on diseased cells....
This Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) is providing $290,325 to the University of Illinois to develop advanced deep learning methods for estimating cell-type resolution and spatially-resolved gene regulatory networks from spatial transcriptomics data. The objectives are to: 1) Create machine learning models that can integrate regulatory network components and distinguish cell types...
This $259,446 Project Grant awarded by the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) will support the development of semi-supervised machine learning integration tools to predict various types of single-cell profiles, such as chromatin accessibility, spatial locations, and proteomics, from known gene expression measurements. The research plan has three key aims: 1) Computationally fill in gaps in single-cell time series data to infer continuous cellular...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $202,274 to develop an easy-to-use computer program for predicting the structure and degrading efficiency of proteolysis targeting chimeras (PROTACs). PROTACs are heterobifunctional molecules that induce the degradation of target proteins by recruiting them to E3 ubiquitin ligases. The awarded project aims to implement a...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) provides $1,203,701 to The Research Foundation For The State University Of New York to conduct research aimed at improving drug development processes. The key focus areas include: Selectively targeting the inactive state of human protein kinases to rapidly identify promising new drug targets, including through the use of novel ATP-allosteric...
This $536,250 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop computational methods that can identify and study rare cell populations in single-cell transcriptomic data. The 2-year project, which runs from July 2025 to June 2027, will design and implement an "autoencoder" artificial neural network framework that can incorporate external knowledge about marker genes or...
This Project Grant award from the National Human Genome Research Institute (NHGRI), part of the Human Genome Research program (CFDA 93.172), provides $1,341,011 to the University of Pittsburgh to develop a novel computational framework integrating deep learning and causal discovery algorithms. The goal is to unveil the individualized (or instance-specific) cell-cell communication networks underlying tissue environment heterogeneity in both normal and disease conditions. The research will involve...
This three-year, $2.3 million project grant from the Department of Health and Human Services will support the development of deep learning and imaging-based methods to map biological networks at the single-cell level. Funded under the National Institute of General Medical Sciences' Biomedical Research and Research Training program, the California Institute of Technology will use large-scale image annotation, machine learning techniques, and cloud computing to solve key challenges in spatial...

DEEP LEARNING METHODS TO ACCELERATE DISCOVERYOF DRUGS TARGETING GENE REGULATORY PROTEINS - SUMMARY TO EVALUATE HOW A DRUG CANDIDATE AFFECTS CELLS, RESEARCHERS OFTEN STUDY HOW THE ABUNDANCE OR BEHAVIOR OF A SPECIFIC SET OF PROTEINS IS CHANGED BY TREATMENT WITH EACH COMPOUND. HOWEVER, IT IS NOT CURRENTLY POSSIBLE TO TEST THE EFFECT OF EVERY POSSIBLE DRUG COMPOUND (>500,000) ON EVERY HUMAN PROTEIN (~20,000) IN HUNDREDS OF DIFFERENT TYPES OF CELLS. EVEN THE MOST ADVANCED PROTEIN ANALYSIS SYSTEMS AVAILABLE TODAY COULD ONLY MEASURE AND PROCESS A TINY FRACTION OF THESE COMBINATIONS IN A FEASIBLE TIMEFRAME. ONE METHOD OF MEASURING THE ABUNDANCE OF ALL THE PROTEINS IN A CELL SAMPLE IS MASS SPECTROMETRY, BUT AVAILABLE INSTRUMENTS CAN ONLY ANALYZE SEVERAL SAMPLES PER DAY. TO INCREASE THE THROUGHPUT OF THESE MASS SPECTROMETRY EXPERIMENTS, IN AIM 1 OF THE PROPOSED PROJECT WE WILL DEVELOP A MACHINE LEARNING ALGORITHM THAT WILL RECONSTRUCT THE PEPTIDE COMPOSITION OF A LARGE NUMBER OF SAMPLES FROM MEASUREMENTS OF A SMALLER NUMBER OF MIXTURES OF THOSE SAMPLES. THIS TECHNOLOGY, CALLED "COMPRESSED SENSING" WAS DEVELOPED FOR DIGITAL IMAGING TO REDUCE (COM- PRESS) THE FILE SIZE OF AN IMAGE. IMPORTANTLY, IT CAN ALSO "DECOMPRESS" A LOW AMOUNT OF COLLECTED INFORMATION TO RECONSTRUCT AN IMAGE WITH SURPRISINGLY HIGH DETAIL. SIMILARLY, WE WILL DEVELOP A COMPRESSED SENSING ALGORITHM TO EXTRACT THE INDIVIDUAL PROTEIN PROFILES FROM MIXTURES OF MULTIPLE COMBINED SAMPLES. INITIALLY, THIS APPROACH WILL ANALYZE 1,000 SAMPLES FROM 250 MEASUREMENTS OF MIXTURES OF THOSE SAMPLES, PROVIDING A 4-FOLD INCREASE IN SPEED. ULTIMATELY, WITH A MUCH HIGHER NUMBER OF SAMPLES, IT MAY ALLOW A 100-FOLD INCREASE IN SAMPLES ANALYZED. TO ACCELERATE INTERPRETATION OF THIS TYPE OF DATA FOR DRUG DISCOVERY, WE WILL CREATE A MACHINE LEARNING ALGORITHM TO SIMPLIFY COMPLEX PATTERNS OF INTERACTIONS BETWEEN TEST COMPOUNDS AND THE PROTEINS WITHIN VARIOUS TYPES OF CELLS. PREVIOUSLY ACQUIRED DATA WILL BE MODELED TO LEARN THE EFFECTS OF INDIVIDUAL COMPOUNDS ON VARIOUS PROTEINS. BY LEARNING FROM A LARGE NUMBER OF THESE DATA SETS THAT DESCRIBE INTERACTIONS BETWEEN SPECIFIC COMPOUNDS AND PROTEINS, IN MANY DIFFERENT CELL TYPES, THE MODEL WILL BE ABLE TO PREDICT THE EFFECT OF UNTESTED COMPOUNDS ON PROTEINS WITHIN VARIOUS TYPES OF CELLS. IN ADDITION, IT WILL BE ABLE TO INDICATE WHICH EXPERIMENTS WOULD BE MOST USEFUL TO PERFORM IN THE FUTURE, TO OBTAIN INFORMATION ON CLASSES OF COMPOUNDS OR PROTEINS THAT ARE LACKING IN THE CURRENT DATA SETS. THE COMBINATION OF THESE TWO TECHNIQUES HAS THE POTENTIAL TO GREATLY ACCELERATE DEVELOPMENT OF NOVEL DRUGS BY PROVIDING A POTENTIALLY HUGE INCREASE IN PROTEIN ABUNDANCE MEASUREMENTS, ALONG WITH A POWERFUL METHOD TO PREDICT HOW DRUGS WILL ALTER THE EXPRESSION OF PROTEINS IN CELLS.

Posted 9/20/23, 12:00 AM